Figure 17. Probability of survival according to the number of bone metastases in previously untreated stage D2 prostate cancer patients who received combination therapy with flutamide and the luteinizing hormone-releasing hormone (LHRH) agonist [D-Trp6, des-Gly-NH210]-LHRH ethylamide.